How Much Weight Can You Lose on Mounjaro?

Summary: At 72 weeks the average tirzepatide patient lost 15.0% of body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg in the SURMOUNT-1 trial. For a 240-pound starting weight that is 36 to 50 pounds, and the number rises with dose, adherence, and how long you stay on the drug.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: in the SURMOUNT-1 trial, adults on tirzepatide lost an average of 15.0% of body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg after 72 weeks, compared with 3.1% on placebo ^[1]. For a 240-pound starting weight that works out to 36 pounds, 47 pounds, and 50 pounds respectively. Mounjaro is the type 2 diabetes brand of tirzepatide; Zepbound is the obesity brand. Same molecule, same dose strengths, same weight loss results when the patient takes the same dose. People who tolerate the higher maintenance doses and stay on treatment for 18 months hit the top of that range.

The rest of the picture is dose, time, body composition, and what happens when you stop.

What SURMOUNT-1 actually measured

SURMOUNT-1 was the pivotal phase 3 trial that supported Zepbound's FDA approval for chronic weight management. It enrolled 2,539 adults with obesity (BMI 30 or higher) or with overweight (BMI 27 to 29.9) plus at least one weight-related condition, excluding type 2 diabetes. Participants were randomized to 5 mg, 10 mg, or 15 mg weekly tirzepatide, or placebo, alongside lifestyle counseling, for 72 weeks ^[1].

The headline result was the percent of starting body weight lost at week 72:

Some published summaries cite slightly higher numbers (16.0%, 21.4%, 22.5%) because two analyses exist: the treatment-regimen estimand (which counts everyone regardless of whether they kept taking the drug) and the efficacy estimand (people who stayed on treatment as planned). The efficacy figures are the larger ones. Both are real. The treatment-regimen numbers reflect what happens in the messy real world where some people stop.

The proportion of participants who lost at least 20% of their body weight was 30% on 5 mg, 50% on 10 mg, and 57% on 15 mg ^[1]. About one in three people on the top dose lost 25% or more. Those are clinical-trial conditions with structured support, so do not assume the median patient outside a trial hits the same number, but the curve is real.

Mounjaro versus Zepbound: same drug, different label

Tirzepatide is the active ingredient in both Mounjaro and Zepbound. Eli Lilly sells the molecule under two names because the FDA approves drugs by indication. Mounjaro is approved for type 2 diabetes ^[2]. Zepbound is approved for chronic weight management in adults with obesity, or with overweight and a weight-related condition ^[3]. The pens are clinically identical inside. The 2.5, 5, 7.5, 10, 12.5, and 15 mg dose strengths are identical. Weight loss from tirzepatide is the same regardless of which label is on the pen.

Why this matters for "how much weight can you lose on Mounjaro": the SURMOUNT trials studied tirzepatide in people without diabetes. Mounjaro is technically prescribed for diabetics. In the SURPASS trials, which tested tirzepatide for type 2 diabetes, the weight loss numbers were a bit lower than SURMOUNT because people with diabetes generally lose less weight on GLP-1 drugs than people without diabetes do. SURPASS-2 reported 7.8 kg, 10.3 kg, and 12.4 kg of weight loss on 5 mg, 10 mg, and 15 mg over 40 weeks, versus 6.2 kg for semaglutide 1 mg ^[5]. If you are on Mounjaro for diabetes, expect your weight loss to land somewhere between the SURMOUNT and SURPASS curves depending on your A1C, how long you have had diabetes, and your insulin resistance.

Month-by-month timeline

Tirzepatide titrates up slowly because the gut needs time to adapt to slowed gastric emptying. That titration determines how fast the scale moves. Here is the typical curve drawn from SURMOUNT-1 and SURPASS data, assuming standard dose escalation.

The first month is the slowest. You are on 2.5 mg, which is a tolerance-building dose, not a therapeutic one. Some of the early drop is water weight from glycogen depletion when appetite suppression kicks in and you eat less starch. Real fat loss accelerates from month two onward as the dose climbs and the daily calorie gap widens.

The biggest gains happen between months three and twelve. By month six most people have lost about 15% of their starting weight if they are pushing toward the 15 mg dose. From month twelve to eighteen the curve flattens; you are still losing, but the rate slows because your body has adapted, your maintenance calorie needs have fallen with your body mass, and your appetite returns somewhat as the body counter-regulates with hormones like ghrelin.

Dose breakdown: do you need 15 mg?

The clinical answer is no, you don't always need to climb to 15 mg. Many patients reach their target on 10 mg or even 5 mg. The question is what you are optimizing for: maximum weight loss or maximum tolerability.

5 mg

The starting maintenance dose. SURMOUNT-1 showed 15.0% average weight loss at 72 weeks ^[1]. About 75% of participants on 5 mg lost at least 5% of body weight, which is the standard clinical threshold for meaningful metabolic benefit. Side effects are usually mild to moderate. If you are losing weight steadily on 5 mg with tolerable side effects, there is no clinical urgency to push higher.

10 mg

The middle therapeutic dose. SURMOUNT-1 showed 19.5% average weight loss ^[1]. About 73% of participants lost at least 15% of body weight. This is where most people land when their clinician balances weight loss against side effects.

15 mg

The maximum dose. SURMOUNT-1 showed 20.9% average weight loss, with 57% of participants losing 20% or more, and roughly 36% losing 25% or more ^[1]. Side effect intensity is higher; nausea, diarrhea, and constipation are more common, though most people who tolerated escalation through 10 mg also tolerate 15 mg.

There is a real dose-response. Higher doses produce more weight loss on average. But that gain plateaus, the difference between 10 mg and 15 mg is about 1.5 percentage points of body weight, smaller than the gap between 5 mg and 10 mg. For most people the meaningful question is whether they can sit comfortably on 10 mg or 15 mg long term, not whether they hit the top number once.

What changes individual results

Trial averages hide a wide distribution. Some SURMOUNT-1 participants on 15 mg lost 35% of their starting weight; others lost almost nothing. The factors that shift you up or down the curve are mostly known.

Starting weight

Heavier patients lose more absolute pounds because the same percentage applies to a bigger base. A 300-pound starter losing 20% drops 60 pounds; a 180-pound starter losing 20% drops 36 pounds. Percentage loss is roughly similar across starting weights, which is why clinical trials report percent of body weight rather than pounds.

Sex

Women in SURMOUNT-1 lost slightly more on average than men, partly because the dosing is fixed at the same milligrams regardless of body size, so women on average received a higher dose relative to body weight. Men typically lose more absolute pounds in the early months because of higher baseline lean mass and metabolic rate, then the curves converge.

Age

Adults over 65 still lose meaningful weight on tirzepatide, but the average is one to two percentage points lower than in younger adults. Slower metabolism, lower lean mass, and reduced appetite at baseline all contribute. The FDA label has no upper age limit ^[2][3].

Adherence

This is the biggest swing factor that you control. Skipping doses, staying too long at sub-therapeutic doses because of side effects, or taking weeks off between refills all reduce total weight loss. In the trial, weight loss tracked closely with cumulative drug exposure.

Diet and exercise

Tirzepatide makes a calorie deficit easier by suppressing appetite. It does not create a deficit by itself. People who keep eating the same number of calories despite reduced hunger lose less. People who eat in line with their new appetite and add protein and resistance training preserve muscle and keep the weight off longer. The SURMOUNT participants also received structured lifestyle counseling, which is not free in the real world.

Insulin resistance and type 2 diabetes

People with diabetes lose about a third less weight on average than people without diabetes do, on the same dose, for the same duration. This is a consistent finding across the GLP-1 class. Mounjaro patients with diabetes can still expect 12% to 16% body weight loss at the top dose, just not the 20%+ that non-diabetics hit.

PCOS, hypothyroidism, certain antidepressants

Conditions and medications that drive weight gain or slow metabolism can blunt response. The drug still works, the number just comes in lower. If your weight loss stalls and you have not investigated underlying endocrine factors, that is the conversation to have with your prescriber.

What happens when you stop

This is the part most articles understate. Tirzepatide treats obesity as a chronic disease. When you stop the drug, the disease is still there.

The SURMOUNT-4 trial gave the cleanest answer to this question. Participants took tirzepatide for 36 weeks, then were randomized to continue tirzepatide or switch to placebo. Over the next 52 weeks, the placebo group regained 14% of their body weight while the tirzepatide group lost an additional 5.5% ^[4]. By the end of the trial, people who stopped had given back about half of what they lost.

This is the same pattern observed with semaglutide in the STEP-4 trial and with most chronic weight medications. The drug suppresses appetite and slows gastric emptying. Stop the drug, those effects fade within weeks, appetite climbs back, body weight defends itself. This is biology, not lack of willpower.

Comparison to other drugs

Tirzepatide produces more weight loss than semaglutide (Ozempic, Wegovy) at maximum doses. SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in people with type 2 diabetes; tirzepatide 15 mg led to 12.4 kg of weight loss versus 6.2 kg for semaglutide ^[5]. The SURMOUNT-5 trial published in 2025 ran a head-to-head between tirzepatide and semaglutide 2.4 mg (Wegovy dose) for obesity and found tirzepatide delivered roughly 47% more weight loss at 72 weeks.

That said, semaglutide is still a strong drug. A 15% average weight loss at top dose is itself historically remarkable. If cost, availability, or tolerability point toward semaglutide, you are not getting a placebo, you are getting a slightly smaller version of the same effect.

Older weight loss drugs (phentermine, orlistat, naltrexone-bupropion) produce 3% to 7% weight loss on average. Bariatric surgery still beats both classes of GLP-1 drugs at the population level, particularly for sustained 10-year results, but tirzepatide closes much of the gap without a procedure.

Does Mounjaro reduce belly fat specifically?

Yes, but not selectively. Tirzepatide reduces total fat mass, and visceral fat (the deep abdominal fat that wraps around organs) typically drops faster than subcutaneous fat. SURMOUNT-1 body composition substudies showed fat mass fell by about 33.9% on average in the tirzepatide group, compared with 8.2% on placebo, with a disproportionate reduction in visceral adipose tissue. So yes, your waistline shrinks faster than the scale alone suggests, particularly if your weight gain was central. You cannot target spot loss with the drug any more than you can with diet, but the natural pattern of GLP-1 induced weight loss is favorable for cardiometabolic risk.

Realistic expectations

If you start Mounjaro at 240 pounds and stay on it for 18 months, escalating to 15 mg, doing the diet and movement work, your expected weight loss is roughly 45 to 55 pounds. That is the SURMOUNT-1 average. About one in three people exceed that range; about one in three fall below it. Total non-responders (less than 5% weight loss) exist but are uncommon at the higher doses.

If you start at 200 pounds and tolerate only 5 mg long term, expect 25 to 35 pounds at 72 weeks. If you have type 2 diabetes, subtract a few pounds from those estimates. If you stop the drug without lifestyle structure in place, expect to give back about half within a year.

This is a medication, not a procedure or a cure. The numbers are real, but they require staying on the drug, dosing consistently, and not relying on the appetite suppression alone to do the work.

Frequently asked questions

How quickly do you lose weight on Mounjaro?

Most people lose 2% to 4% of body weight in the first month on 2.5 mg, then accelerate through months two to six as the dose climbs. The 15 mg average at 18 months in SURMOUNT-1 was 20.9%.

Is Mounjaro the same as Zepbound?

Yes, both contain tirzepatide at identical strengths. Mounjaro is the brand approved for type 2 diabetes; Zepbound is the brand approved for weight management. Same drug, same dose, same weight loss.

Why am I not losing weight on Mounjaro at 5 mg, 7.5 mg, or 15 mg?

Common reasons include eating in line with old appetite rather than new appetite, alcohol or liquid calories that bypass GLP-1 satiety signaling, untreated insulin resistance or hypothyroidism, and not enough time at therapeutic dose. Stalls in the first 8 weeks of any new dose are normal. Stalls beyond 12 weeks at maximum dose deserve a clinical conversation.

Do you lose more weight on a higher dose of Mounjaro?

On average yes. SURMOUNT-1 showed 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. The gain from 10 mg to 15 mg is smaller than the gain from 5 mg to 10 mg, and some people do as well on 10 mg as on 15 mg.

How much weight will I lose on Mounjaro in 3 months?

Clinical trial averages were 5% to 10% of starting body weight in the first three months. That equals 12 to 24 pounds for someone starting at 240 pounds. Patients on more aggressive dose escalation land toward the top of that range.

Will I gain the weight back if I stop Mounjaro?

Most people do. The SURMOUNT-4 trial showed an average 14% body weight regain in the year after stopping tirzepatide, while continued treatment produced an additional 5.5% loss. Obesity is a chronic condition that the drug treats but does not cure.

Will Mounjaro get rid of belly fat?

Yes. Visceral abdominal fat drops faster than subcutaneous fat on tirzepatide, so waist circumference typically decreases more than overall weight loss alone would predict. You cannot target the loss to the belly specifically, but the natural pattern favors central fat reduction.

Does Mounjaro work for skinny people or people with a normal BMI?

The FDA label requires BMI 30 or higher, or BMI 27+ with a weight-related condition. People at normal BMI were not studied and prescribers will not write the drug for them. Below those thresholds the risk-benefit balance is not established.

How does Mounjaro compare to Ozempic for weight loss?

Tirzepatide produces more weight loss than semaglutide at maximum doses. Head-to-head SURPASS-2 data showed 12.4 kg loss on tirzepatide 15 mg versus 6.2 kg on semaglutide 1 mg in type 2 diabetes. SURMOUNT-5 confirmed a similar gap in obesity at maximum doses.

Do you lose muscle on Mounjaro?

Yes, some. About 25% of total weight lost on tirzepatide is lean mass, which tracks with what is seen in any rapid weight loss including bariatric surgery. Protein intake of roughly 0.8 to 1.0 grams per pound of goal body weight and resistance training preserve most of the muscle.

Can men and women expect different weight loss on Mounjaro?

Women lost slightly more than men in SURMOUNT-1, partly because fixed milligram dosing delivers a higher dose per kilogram in smaller bodies. The difference is a few percentage points and individual variation dwarfs the sex difference.

How long do I need to stay on Mounjaro to keep the weight off?

Indefinitely, for most people, unless lifestyle and body composition changes are deep enough to hold without the drug. Stopping leads to partial regain in the majority of patients. Many clinicians transition long-term patients to a lower maintenance dose (2.5 mg or 5 mg) rather than full discontinuation.

What this page does not cover

This page is the average, the curves, and the variability. For dose-specific side effects (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), titration timing, injection technique, what to eat, how to manage plateaus, cost and coupons, and what to do if you switch from Mounjaro to Zepbound or Wegovy, see the dedicated pages on this site. The weight loss numbers here come from SURMOUNT-1 ^[1] and SURMOUNT-4 ^[4], with the diabetes context from SURPASS-2 ^[5], and the dosing rules from the FDA labels for Mounjaro ^[2] and Zepbound ^[3].